Investor Relations

- Dr. Christian Hassig, CSO, scheduled to present at 10:00 a.m. ET on March 13, 2019 - VANCOUVER, March 5, 2019 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development...

- Momelotinib regulatory pathway clarity anticipated in H1 2019 - - SRA737 preliminary data anticipated in H1 2019 - VANCOUVER, Feb. 28, 2019 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a...

- Late-breaking oral presentation to report preclinical mechanistic and efficacy data for immunotherapy combined with SRA737 + LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small...